Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Sponsor
Harbin Medical University
Study ID
NCT06192680
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This multicenter, single-arm trial will explore the efficacy and safety of liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer.

Key Dates

Start date
Apr 1, 2024
Status verified
Jan 2024
Primary completion
Nov 30, 2025
Completion
Sep 30, 2026

Study Design

Enrollment
63 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: liposomal irinotecan + capecitabine + bevacizumab
    liposomal irinotecan 70 mg/m², d1 + capecitabine 1000 mg/m² BID, d1\~10 + bevacizumab 5mg/kg, d1. q2w

Primary Outcome Measure

Progression free Survival [ Time Frame: 1 year ]

Central Contacts

Related Studies